home / stock / zgnx / zgnx news

ZGNX News and Press, Zogenix Inc. From 12/17/19

Stock Information
Company Name: Zogenix Inc.
Stock Symbol: ZGNX
Market: NASDAQ
Website: zogenix.com
Menu
ZGNX ZGNX Quote ZGNX Short ZGNX News ZGNX Articles ZGNX Message Board
Get ZGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ZGNX - The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome

FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare ...
ZGNX - Zogenix (ZGNX) Presents At American Epilepsy Society 2019 Annual Meeting - Slideshow

The following slide deck was published by Zogenix, Inc. in conjunction with this Read more ...

ZGNX - Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), ...

ZGNX - JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

Addition of FINTEPLA to stiripentol-inclusive regimens provided a 54% greater reduction in study patients’ mean monthly convulsive seizure frequency compared to placebo A significantly greater proportion of study patients taking FINTEPLA compared to placebo experienced clinica...
ZGNX - Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting

EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its investigational therapy, FINTEPLA ® (ZX008, fenfluramine oral solution), for t...

ZGNX - Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Thursday, December 5, 2019, at the 31 st Annual Piper J...

ZGNX - FDA OKs Zogenix's Fintepla for Dravet syndrome

Under Priority Review status, the FDA has accepted Zogenix's (NASDAQ: ZGNX ) NDA for FINTEPLA (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet syndrome. More news on: Zogenix, Inc., Healthcare stocks news, Read more ...

ZGNX - Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

EMERYVILLE, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for...

ZGNX - Zogenix to Present at Two Investor Conferences in November

EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary...

ZGNX - Zogenix Inc (ZGNX) Q3 2019 Earnings Call Transcript

Image source: The Motley Fool. Zogenix Inc   (NASDAQ: ZGNX) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading

Previous 10 Next 10